Angiogenesis 2010: Clinical Trials"In early Q1 2010 iCo expects a last patient visit (month six) followed by data lock and analysis. iCo expects to present final data inQ2 2010."
It's mid Q1 and they most likely had the last visit, so they know enough to make a good presentation. They probably can't say too much without the analysis. I look forward to seeing the slide show.
K
iCo Therapeutics Inc.;iCo-007 for Diabetic Macular Edema to be Presented at Angiogenesis 2010:Clinical Trials
Last Update: 2/19/2010 2:47:11 PM
VANCOUVER, BRITISH COLUMBIA, Feb 19, 2010 (Marketwire via COMTEX) --iCo Therapeutics Inc.(ICO) is pleased to announce that the Company's Diabetic Macular Edema("DME") candidate, iCo-007, will be highlighted in a presentation at"Angiogenesis 2010: Clinical Trials" (website:https://bascompalmer.org/site/info/pdf/Angiogenesis_2010_brochure.pdf).
The conference will be held on Saturday, February 20, 2010 at theMandarin Oriental Hotel in Miami, Florida and will feature prominentscientists, clinicians and healthcare experts in neovascular diseases ofthe eye, including age related macular degeneration and DME. Slideswill be available for viewing on iCo's website.
The primary endpoint of the open label, dose escalating trial is safety,with visual acuity and measures of retinal thickness serving assecondary endpoints. Four U.S. clinical sites are participating.
About iCo-007
Designed and discovered by ISIS Pharmaceuticals Inc.(ISIS), iCo-007 is a second-generation antisense drug targeting c-Rafkinase for the treatment of DME and diabetic retinopathy.
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focusedon redosing or reformulating drugs with clinical history for new orexpanded indications. iCo has exclusive worldwide rights to threeproducts: iCo-007, in Phase I for the treatment of DME, iCo-008; aproduct with Phase II clinical history to be developed for severe ocularallergies; and iCo-009, an oral formulation of Amphotericin B for sightand life - threatening diseases. iCo-009 also represents a new drugdelivery technology with the potential to reprofile other parenteraladministered drugs to the oral route of administration. iCo Therapeuticstrades on the TSX-Venture exchange under the symbol "ICO". For moreinformation, visit the company website at:www.icotherapeutics.com
Forward Looking Statements
Certain statements included in this press release may be consideredforward-looking. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results,performance or achievements to be materially different from thoseimplied by such statements, and therefore these statements should not beread as guarantees of future performance or results. Allforward-looking statements are based on iCo Therapeutics' currentbeliefs as well as assumptions made by and information currentlyavailable to iCo Therapeutics and relate to, among other things,anticipated financial performance, business prospects, strategies,regulatory developments, market acceptance and future commitments.Readers are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date of thispress release. Due to risks and uncertainties, including the risks anduncertainties identified by iCo Therapeutics in its public securitiesfilings; actual events may differ materially from current expectations.iCo Therapeutics disclaims any intention or obligation to update orrevise any forward-looking statements, whether as a result of newinformation, future events or otherwise.
SOURCE: iCo Therapeutics Inc.
iCo Therapeutics Inc. - Investor Relations
John Meekison
CFO
604-602-9414
www.icotherapeutics.com
Copyright (C) 2010 Marketwire. All rights reserved.
<<Returnto previous